Behavioral side effects of triazolam in psychiatric inpatients: report of five cases.
Triazolam was administered to five psychiatric inpatients for a two-week period. This period was preceded by a one-week placebo baseline and followed by another week of placebo administration. All conditions were double blind. By the second week of active drug administration, psychopathology greatly intensified across all of the patients with the emergence of anxiety, memory impairment, confusion, paranoid ideation, and hallucinations. The drug-induced behavioral changes persisted during the initial withdrawal period, but then gradually subsided. Also following drug withdrawal, four patients showed a marked worsening of their sleeplessness for several nights.
D000328:Adult; D002986:Clinical Trials as Topic; D003863:Depression / Q000150:complications / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006760:Hospitalization; D006801:Humans; D008297:Male; D008875:Middle Aged; D011605:Psychoses, Substance-Induced; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy*; D007319:Sleep Initiation and Maintenance Disorders / Q000150:complications / Q000188:drug therapy*; D014229:Triazolam / Q000009:adverse effects* / Q000627:therapeutic use
D014229:Triazolam